AU2002237667A1 - Methods for the treatment and prevention of urinary stone disease - Google Patents

Methods for the treatment and prevention of urinary stone disease

Info

Publication number
AU2002237667A1
AU2002237667A1 AU2002237667A AU3766702A AU2002237667A1 AU 2002237667 A1 AU2002237667 A1 AU 2002237667A1 AU 2002237667 A AU2002237667 A AU 2002237667A AU 3766702 A AU3766702 A AU 3766702A AU 2002237667 A1 AU2002237667 A1 AU 2002237667A1
Authority
AU
Australia
Prior art keywords
prevention
treatment
methods
urinary stone
stone disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002237667A
Inventor
Billy Hudson
Jon Scheimman
Paul Voziyan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kansas Medical Center
Original Assignee
University of Kansas Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Kansas Medical Center filed Critical University of Kansas Medical Center
Publication of AU2002237667A1 publication Critical patent/AU2002237667A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
AU2002237667A 2000-11-20 2001-11-14 Methods for the treatment and prevention of urinary stone disease Abandoned AU2002237667A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24999100P 2000-11-20 2000-11-20
US60/249,991 2000-11-20
PCT/US2001/043775 WO2002039994A2 (en) 2000-11-20 2001-11-14 Methods for the treatment and prevention of urinary stone disease

Publications (1)

Publication Number Publication Date
AU2002237667A1 true AU2002237667A1 (en) 2002-05-27

Family

ID=22945853

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002237667A Abandoned AU2002237667A1 (en) 2000-11-20 2001-11-14 Methods for the treatment and prevention of urinary stone disease

Country Status (3)

Country Link
US (2) US6521645B2 (en)
AU (1) AU2002237667A1 (en)
WO (1) WO2002039994A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750209B1 (en) * 1995-09-12 2004-06-15 Kansas University Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
US6436969B1 (en) * 1995-09-12 2002-08-20 Kansas University Medical Center Research Institute Inc. Dialysis solutions and methods
US7030146B2 (en) * 1996-09-10 2006-04-18 University Of South Carolina Methods for treating diabetic neuropathy
US6768189B1 (en) * 2003-06-04 2004-07-27 Northrop Grumman Corporation High power chip scale package
US20090082407A1 (en) * 2004-06-18 2009-03-26 Biostratum, Inc. Pyridoxamine for the Treatment of Diabetic Kidney Disease
PT1643999E (en) * 2003-06-20 2012-01-09 Nephrogenex Inc Pyridoxamine for use in the treatment of diabetic neprhopathy in type ii diabetes
US7335187B2 (en) 2003-10-14 2008-02-26 Sda Product, Inc. Safety dialysis needle/catheter system and method of use
WO2005077902A2 (en) * 2004-02-09 2005-08-25 Biostratum, Inc. Methods for the synthesis of pyridoxamine
US7195891B2 (en) * 2004-08-11 2007-03-27 General Atomics Methods and compositions of enzymatic cycling based assays for myeloperoxidase
KR100819702B1 (en) * 2006-02-15 2008-04-04 엔에이치엔(주) Method and system for exposing games
US20150216825A1 (en) * 2014-02-06 2015-08-06 University Of Houston System Organic acids as growth inhibitors of pathological calcification and uses thereof
US10285961B2 (en) 2014-02-06 2019-05-14 University Of Houston System Organic acids as agents to dissolve calcium minerals in pathological calcification and uses thereof
US11603524B2 (en) 2015-04-02 2023-03-14 Oxidien Pharmaceuticals, Llc High efficiency oxalate-degrading enzymes for degradation of insoluble and soluble oxalate
EP3386967A4 (en) * 2015-12-07 2020-03-25 Wake Forest University Health Sciences Combinations for the treatment of kidney stones
CA3013666C (en) * 2016-02-15 2023-12-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of stiripentol and their derivatives for decreasing urinary oxalate concentration in an individual
JP2021523139A (en) * 2018-05-08 2021-09-02 イエール ユニバーシティ Compositions and methods for slowing the progression of nephrolithiasis
CN115006465B (en) * 2022-07-13 2023-06-13 四川省畜牧科学研究院 Flushing fluid for treating animal urinary calculus and preparation method thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4665192A (en) 1984-03-19 1987-05-12 The Rockefeller University 2-(2-furoyl)-4(5)-2(furanyl)-1H-imidazole
US4758583A (en) 1984-03-19 1988-07-19 The Rockefeller University Method and agents for inhibiting protein aging
US5254572A (en) 1987-11-27 1993-10-19 Vesta Medicines (Pty) Ltd. Method and composition for supplementing vitamin B6 where the PN-PLP pathway is disturbed
US5631271A (en) 1986-11-29 1997-05-20 Serfontein; Willem J. Methods and preparations for the treatment and prophylaxis of metabolic disturbances
US5288716A (en) 1987-02-18 1994-02-22 Ulrich Speck Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis
DE4033530A1 (en) * 1990-10-22 1992-04-23 Univ Schiller Jena Crystallisation inhibitor for treating kidney stone disorders - contains an ethanolic extract of madder contg. 0.2-1.0 per cent ruberythric acid
FR2750605B1 (en) * 1995-01-13 1998-09-25 Komissarova Irina Alexeevna PHARMACEUTICAL COMPOSITION WITH ANTI-ALCOHOLIC AND NOOTROPIC EFFECTS
US6228858B1 (en) 1995-09-12 2001-05-08 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US6051587A (en) 1998-04-16 2000-04-18 Medicure, Inc. Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein
US6043259A (en) 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
AU1444600A (en) 1998-10-09 2000-05-01 Kansas University Medical Center Methods for inhibiting oxidative modification of proteins
AU1112500A (en) 1998-10-14 2000-05-01 Kansas University Medical Center Research Institute, Inc. Methods for inhibiting diabetic complications
JP3864050B2 (en) 1998-10-22 2006-12-27 ユニヴァースティ オブ サウス カロライナ Pharmaceutical composition for treating or preventing diabetic complications
CA2360311C (en) 1999-04-06 2003-03-18 Raja Khalifah Improved dialysis solutions and methods

Also Published As

Publication number Publication date
WO2002039994A2 (en) 2002-05-23
WO2002039994A3 (en) 2003-08-21
US20020115694A1 (en) 2002-08-22
US20030060490A1 (en) 2003-03-27
US6521645B2 (en) 2003-02-18

Similar Documents

Publication Publication Date Title
WO2001078781A8 (en) Methods for prevention and treatment of gastrointestinal disorders
AU2001275257A1 (en) Methods and devices for the treatment of urinary incontinence
AU2002219472A1 (en) Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
EP1416961A4 (en) Composition and method for the treatment of disease
AU6147401A (en) Compositions and methods for the treatment of cancer
AU2001259758A1 (en) Interleukin-1 inhibitors in the treatment of diseases
AU2072201A (en) Agents and methods for the treatment of proliferative diseases
AU2002239491A1 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
AU2002237667A1 (en) Methods for the treatment and prevention of urinary stone disease
AU2001283285A1 (en) Antimicrobial composition and methods of use in the treatment of disease
AU2001250821A1 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
AU2001286983A1 (en) Method of treatment
MXPA03003741A (en) Methods and compositions for the treatment of diseases of the eye.
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
AU2002220266A1 (en) Methods for the identification and the treatment of cardiovascular disease
AU2001232345A1 (en) Compositions for preventing and treating digestive diseases
AU5565401A (en) Materials and methods for the treatment of depression
AU2001262177A1 (en) Method of treatment
AU2001267165A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU2002222125A1 (en) Prevention and treatment of tachyphylactic response
AU2002256967A1 (en) Treating or reducing the risk of cardiovascular disease
AU2001255168A1 (en) Compositions and methods for the treatment of immune related diseases
AU2001281465A1 (en) Treatment of rosacea
AU2001253560A1 (en) Methods of treatment
AU2002342188A1 (en) Methods and compositions for treating flavivirus-mediated disease